Cole Billena1, Molly Wilgucki1, Jessica Flynn2, Leslie Modlin1, Audree Tadros3, Pedram Razavi4, Lior Z Braunstein1, Erin Gillespie1, Oren Cahlon1, Beryl McCormick1, Zhigang Zhang2, Monica Morrow3, Simon Powell1, Atif J Khan5. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York City, New York. 2. Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, New York. 3. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York. 4. Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York. 5. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York City, New York. Electronic address: khana7@mskcc.org.
Abstract
PURPOSE: Breast cancer diagnosis at a very young age has been independently correlated with worse outcomes. Appropriately intensifying treatment in these patients is warranted, even as we acknowledge the risks of potentially mutagenic adjuvant therapies. We examined local control, distant control, overall survival, and secondary malignancy rates by age cohort and by initial surgical strategy. METHODS AND MATERIALS: Female patients less than or equal to 35 years of age diagnosed with invasive breast cancer from January 1, 1990, to December 31, 2010, were identified. Control groups of those aged 36 to 50 years (n = 6246) and 51 to 70 years (n = 7294) were delineated from an institutional registry. Clinicopathologic and follow-up information was collected. Chi-squared test was used to compare frequencies of categorical variables. Survival endpoints were evaluated using Kaplan-Meier methodology. RESULTS: A total of 529 patients ≤35 years of age met criteria for analysis. The median age of diagnosis was 32 years (range 20-35). Median follow-up was 10.3 years. On multivariable analysis, factors associated with overall survival (OS) were tumor size (hazard ratio [HR] 1.14, P = .02), presence of lymphovascular invasion (HR 2.2, P <.001), estrogen receptor positivity (HR 0.64, P = .015), receipt of adjuvant chemotherapy (HR 0.52, P = .035), and black race (HR 2.87, P <.001). The ultra-young were more likely to experience local failure compared with the aged 36 to 50 group (HR 2.2, 95% CI 1.8-2.6, P < .001) and aged 51 to 70 group (HR 3.1, 95% CI 2.45 - 3.9, P <.001). The cumulative incidence of secondary malignancies at 5 and 10 years was 2.2% and 4.4%, respectively. Receipt of radiation was not significantly associated with secondary malignancies or contralateral breast cancer. CONCLUSION: Survival and recurrence outcomes in breast cancer patients ≤35 years are worse compared with those aged 36 to 50 or 51 to 70 years. Based on our data, breast conservation therapy is appropriate for these patients, and the concern for second malignancies should not impinge on the known indications for postoperative radiation therapy.
PURPOSE: Breast cancer diagnosis at a very young age has been independently correlated with worse outcomes. Appropriately intensifying treatment in these patients is warranted, even as we acknowledge the risks of potentially mutagenic adjuvant therapies. We examined local control, distant control, overall survival, and secondary malignancy rates by age cohort and by initial surgical strategy. METHODS AND MATERIALS: Female patients less than or equal to 35 years of age diagnosed with invasive breast cancer from January 1, 1990, to December 31, 2010, were identified. Control groups of those aged 36 to 50 years (n = 6246) and 51 to 70 years (n = 7294) were delineated from an institutional registry. Clinicopathologic and follow-up information was collected. Chi-squared test was used to compare frequencies of categorical variables. Survival endpoints were evaluated using Kaplan-Meier methodology. RESULTS: A total of 529 patients ≤35 years of age met criteria for analysis. The median age of diagnosis was 32 years (range 20-35). Median follow-up was 10.3 years. On multivariable analysis, factors associated with overall survival (OS) were tumor size (hazard ratio [HR] 1.14, P = .02), presence of lymphovascular invasion (HR 2.2, P <.001), estrogen receptor positivity (HR 0.64, P = .015), receipt of adjuvant chemotherapy (HR 0.52, P = .035), and black race (HR 2.87, P <.001). The ultra-young were more likely to experience local failure compared with the aged 36 to 50 group (HR 2.2, 95% CI 1.8-2.6, P < .001) and aged 51 to 70 group (HR 3.1, 95% CI 2.45 - 3.9, P <.001). The cumulative incidence of secondary malignancies at 5 and 10 years was 2.2% and 4.4%, respectively. Receipt of radiation was not significantly associated with secondary malignancies or contralateral breast cancer. CONCLUSION: Survival and recurrence outcomes in breast cancer patients ≤35 years are worse compared with those aged 36 to 50 or 51 to 70 years. Based on our data, breast conservation therapy is appropriate for these patients, and the concern for second malignancies should not impinge on the known indications for postoperative radiation therapy.
Authors: Geneviève Coulombe; Scott Tyldesley; Caroline Speers; Chuck Paltiel; Christina Aquino-Parsons; Vanessa Bernstein; Pauline T Truong; Mira Keyes; Ivo A Olivotto Journal: Int J Radiat Oncol Biol Phys Date: 2007-02-01 Impact factor: 7.038
Authors: Irene L Wapnir; Stewart J Anderson; Eleftherios P Mamounas; Charles E Geyer; Jong-Hyeon Jeong; Elizabeth Tan-Chiu; Bernard Fisher; Norman Wolmark Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Enja J Bantema-Joppe; Linda de Munck; Otto Visser; Pax H B Willemse; Johannes A Langendijk; Sabine Siesling; John H Maduro Journal: Int J Radiat Oncol Biol Phys Date: 2011-09-09 Impact factor: 7.038
Authors: A C Voogd; M Nielsen; J L Peterse; M Blichert-Toft; H Bartelink; M Overgaard; G van Tienhoven; K W Andersen; R J Sylvester; J A van Dongen Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Beth M Beadle; Wendy A Woodward; Susan L Tucker; Elesyia D Outlaw; Pamela K Allen; Julia L Oh; Eric A Strom; George H Perkins; Welela Tereffe; Tse-Kuan Yu; Funda Meric-Bernstam; Jennifer K Litton; Thomas A Buchholz Journal: Int J Radiat Oncol Biol Phys Date: 2008-08-15 Impact factor: 7.038
Authors: Jennifer L Gnerlich; Anjali D Deshpande; Donna B Jeffe; Allison Sweet; Nick White; Julie A Margenthaler Journal: J Am Coll Surg Date: 2009-01-21 Impact factor: 6.113
Authors: Jonathan Frandsen; David Ly; George Cannon; Gita Suneja; Cindy Matsen; David K Gaffney; Melissa Wright; Kristine E Kokeny; Matthew M Poppe Journal: Int J Radiat Oncol Biol Phys Date: 2015-09-01 Impact factor: 7.038
Authors: Kate R Pawloski; Andrea V Barrio; Mary L Gemignani; Varadan Sevilimedu; Tiana Le; Joseph Dayan; Monica Morrow; Audree B Tadros Journal: J Am Coll Surg Date: 2021-05-03 Impact factor: 6.532